These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 8205934)
1. In vitro antibacterial activity of FK037, a new parenteral broad-spectrum cephalosporin, against recent clinical isolates in the fields of obstetrics and gynecology. Mikamo H; Izumi K; Ito K; Katoh N; Watanabe K; Ueno K; Tamaya T Chemotherapy; 1994; 40(3):161-6. PubMed ID: 8205934 [TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo antibacterial activities of FK037, a new parenteral cephalosporin. Nishino T; Otsuki M; Hatano K; Nishihara Y Chemotherapy; 1994; 40(3):167-82. PubMed ID: 8205935 [TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo antibacterial activities of FK037, a novel parenteral broad-spectrum cephalosporin. Fu KP; Foleno BD; Lafredo SC; LoCoco JM; Isaacson DM Antimicrob Agents Chemother; 1993 Feb; 37(2):301-7. PubMed ID: 8452361 [TBL] [Abstract][Full Text] [Related]
8. In vivo antibacterial activity of FK037, a novel parenteral broad-spectrum cephalosporin. Mine Y; Watanabe Y; Sakamoto H; Hatano K; Wakai Y; Kamimura T; Tawara S; Matsumoto S; Matsumoto F; Kuwahara S J Antibiot (Tokyo); 1993 Jan; 46(1):88-98. PubMed ID: 8436563 [TBL] [Abstract][Full Text] [Related]
9. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--I. Gram-positive bacteria]. Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T Jpn J Antibiot; 2003 Oct; 56(5):437-57. PubMed ID: 14692380 [TBL] [Abstract][Full Text] [Related]
10. Comparative antimicrobial activity of FK037, cefpirome, ceftazidime and cefepime against aminoglycoside-sensitive and aminoglycoside-resistant Pseudomonas aeruginosa and Pseudomonas spp. Baltch AL; Smith RP; Ritz W Chemotherapy; 1994; 40(6):391-8. PubMed ID: 7842822 [TBL] [Abstract][Full Text] [Related]
11. Ceftizoxime: a beta-lactamase-stable, broad-spectrum cephalosporin. Pharmacokinetics, adverse effects and clinical use. Neu HC Pharmacotherapy; 1984; 4(2):47-60. PubMed ID: 6326062 [TBL] [Abstract][Full Text] [Related]
12. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1996). I. Susceptibility distribution]. Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Shigeta S; Takahashi T; Shiraiwa Y; Ogiwara M; Yoshida H; Imafuku Y; Murai M; Watanabe K; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Igari J; Oguri T; Yamaguchi K; Matsumoto T; Kashitani F; Kaku M; Ooe H; Mochida C Jpn J Antibiot; 1998 Feb; 51(2):69-111. PubMed ID: 9575437 [TBL] [Abstract][Full Text] [Related]
13. [In vitro activities of levofloxacin and other antibiotics against fresh clinical isolates]. Matsuzaki K; Koyama H; Chiba A; Omika K; Harada S; Sato Y; Hasegawa M; Kobayashi I; Kaneko A; Sasaki J Jpn J Antibiot; 1999 Sep; 52(9):571-84. PubMed ID: 10746192 [TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo antibacterial activities of a new carbapenem BO-2727 for use in obstetrics and gynecology. Mikamo H; Kawazoe K; Izumi K; Sato Y; Tamaya T Chemotherapy; 1998; 44(1):12-6. PubMed ID: 9444403 [TBL] [Abstract][Full Text] [Related]
15. [Antimicrobial susceptibility of clinical isolates of aerobic Gram-positive cocci and anaerobic bacteria in 2006]. Yamaguchi T; Yoshida I; Itoh Y; Tachibana M; Takahashi C; Kaku M; Kanemitsu K; Okada M; Horikawa Y; Shiotani J; Kino H; Ono Y; Baba H; Matsuo S; Asari S; Toyokawa M; Matsuoka K; Kusano N; Nose M; Murase M; Miyamoto H; Saikawa T; Hiramatsu K; Kohno S; Yanagihara K; Yamane N; Nakasone I; Maki H; Yamano Y Jpn J Antibiot; 2010 Dec; 63(6):431-56. PubMed ID: 21425596 [TBL] [Abstract][Full Text] [Related]
16. TOC-39, a novel parenteral broad-spectrum cephalosporin with excellent activity against methicillin-resistant Staphylococcus aureus. Hanaki H; Akagi H; Masaru Y; Otani T; Hyodo A; Hiramatsu K Antimicrob Agents Chemother; 1995 May; 39(5):1120-6. PubMed ID: 7625799 [TBL] [Abstract][Full Text] [Related]
17. [In vitro and in vivo activities of sulopenem compared with those of imipenem and cephalosporins]. Nagashima M; Goto S; Yoshida T; Matsunaga T; Shimohira H; Ogawa M Jpn J Antibiot; 1996 Apr; 49(4):303-23. PubMed ID: 8786623 [TBL] [Abstract][Full Text] [Related]
18. In vitro activity of ceftobiprole against aerobic and anaerobic strains isolated from diabetic foot infections. Goldstein EJ; Citron DM; Merriam CV; Warren YA; Tyrrell KL; Fernandez HT Antimicrob Agents Chemother; 2006 Nov; 50(11):3959-62. PubMed ID: 16982780 [TBL] [Abstract][Full Text] [Related]
19. [In vitro activities of sulopenem, a new parenteral penem, against anaerobes]. Watanabe K; Kato N; Tanaka-Bandoh K; Tanaka Y; Kato H; Ueno K Jpn J Antibiot; 1996 Apr; 49(4):367-76. PubMed ID: 8786627 [TBL] [Abstract][Full Text] [Related]
20. In vitro activity of flomoxef compared to moxalactam, cefoxitin, cefotaxime, and clindamycin against anaerobes. Werner H; Heizmann W; Luft G Arzneimittelforschung; 1988 Nov; 38(11):1553-6. PubMed ID: 3214438 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]